Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance
Rhea-AI Summary
Sanuwave Health (NASDAQ: SNWV) reported preliminary, unaudited revenues of $9.6–$9.8 million for Q2 2026, exceeding the high end of its revised guidance of $8.5–$9.5 million. This compares to revenues of $10.1 million in Q2 2025, a decline of approximately 3–5%.
According to Sanuwave, capital equipment sales faced headwinds from customer stress and used Ultramist system sales. The company highlighted record unit and revenue performance in consumable applicator sales and noted that these results may be adjusted upon completion of its Q2 2026 financial close and review.
Positive
- Q2 2026 revenue $9.6–$9.8M, above high end of $8.5–$9.5M guidance
- Consumable applicator sales reached all‑time records in both units and revenue
Negative
- Preliminary Q2 2026 revenue of $9.6–$9.8M is 3–5% lower than $10.1M in Q2 2025
- Company reports headwinds in capital sales from customer stress and used Ultramist systems
News Explained
The July 13 update raises preliminary Q2 revenue above revised guidance, but the figure remains unaudited pending the August earnings report.
The
“Preliminary” means the figures come from management’s initial analysis and remain subject to adjustments during the quarter-end financial close and review process.
The release compares the preliminary Q2 range with
The next named milestone is the company’s Q2 earnings report in
Market reaction after Q2 2026 preliminary revenue update: SNWV +6.22% in the Jul 14 session
In the Jul 14 session, SNWV gained 6.22%, reflecting a notable positive market reaction. Argus tracked a peak move of +16.1% during that session. Argus tracked a trough of -4.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 2026 earnings | Neutral | +18.1% | Modest Q1 revenue growth with weaker profitability but reiterated strong 2026 revenue guidance. |
| Apr 16 | Prelim Q1 2026 | Positive | +14.4% | Preliminary Q1 revenue slightly above prior year and in line with guidance range. |
| Mar 26 | Q4 2025 results | Positive | -1.3% | Record Q4 and full‑year 2025 revenues with strong growth and positive operating income. |
| Jan 9 | Prelim Q4 2025 | Positive | +1.2% | Preliminary Q4 and full‑year 2025 revenues reached record levels with high growth. |
| Nov 7 | Q3 2025 earnings | Positive | +17.7% | Record Q3 revenue with strong year‑over‑year growth and higher sequential performance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-related headlines have generally produced positive share reactions, with one notable divergence on record Q4 2025 results.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Sanuwave announces preliminary, unaudited revenues of
EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of
“Q2 came in a bit above the top of the range that we laid out back in June,” said CEO Morgan Frank. “The business played out largely as we had forecast with capital sales facing headwinds from stress in our customer base and from the sale of used Ultramist systems in our market. Regarding the latter, as we discussed in our last release, Sanuwave will always seek to do what’s best for the patients, so we’ve been working to help qualify, train, and support such new users and offering attractive trade-in terms such that units purchased used can be traded in for certified pre-owned systems that would carry a manufacturer’s warranty. This program has been showing success so far.”
“The good news in the quarter is that sales of consumable applicators set all time records for both unit sales and revenues, both by significant margins. We see this as an indication of both increasing interest and confidence in Ultramist as a wound care modality and, obviously, as consumables are the core of any razor-razorblade business, as a promising trend for the future. We look forward to speaking with you more about this when the Company reports Q2 earnings in August.”
The preliminary revenue results described herein are based on management’s initial analysis of the second quarter ended June 30, 2026, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close and review procedures.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy systems used in the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented and FDA approved/cleared energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are: reductions, clawbacks, or recoupments of CMS reimbursement for skin substitutes, allografts, or other advanced wound care products, and their effect on customer behavior and capital budgets; the financial distress, closure, or liquidation of wound care practices and the resulting impact on demand for the Company's systems; the emergence and growth of a secondary market for used Ultramist systems and the cannibalizing effect of such resales on sales of new systems; the Company's ability to qualify, train, and support new users acquiring systems through the secondary market, and the related regulatory, quality, and product-liability considerations; the Company's ability to sustain applicator and consumable volumes and convert system placements into recurring consumable revenue; any differences between updated guidance and final reported results following completion of the quarter; risks associated with regulatory oversight; the Company's ability to manage its capital resources; competition; and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
